Ralph Niven, CHIEF SCIENTIFIC OFFICER at Aerovate Therapeutics, Inc. (AVTE), sold 4,500 shares at $24.27 ($109K) on 2023-02-06, disclosed to the SEC on 2023-02-08.
Open-market sale of $109k AVTE by CHIEF SCIENTIFIC OFFICER. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.27 | 2,250 | $55K | 50.0% |
| 2 | $24.27 | 2,250 | $55K | 50.0% |
| Total | $24.27 avg | 4,500 | $109K | 100% |
| Filing → |
| AVTE | SELL | 2023-12-07 | $75K | — | Filing → |
| AVTE | SELL | 2023-11-27 | $207K | — | Filing → |
| AVTE | SELL | 2023-07-07 | $39K | — | Filing → |